NovoCure Limited Ordinary Shares

NVCRNASDAQ • USD
11.30 USD
↘ 0.53 (4.48%)AT CLOSE (03:59 PM EST)
11.55
↗ 0.25 (2.23%)
POST MARKET (AS OF 07:55 PM EST)
Post Market
AS OF 07:55 PM EST
11.55
↗ 0.25 (2.23%)
🔴Market: CLOSED

NVCR is currently priced at $11.30. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 16, 2026.

Open?$11.61
High?$11.72
Low?$11.23
Prev. Close?$11.83
Volume?2.4M
Avg. Volume?1.9M
VWAP?$11.48
Rel. Volume?1.29x
Bid / Ask
Bid?$11.25 × 300
Ask?$11.85 × 1.5K
Spread?$0.60
Midpoint?$11.55
Valuation & Ratios
Market Cap?1.3B
Shares Out?116.9M
Float?105.4M
Float %?90.5%
P/E Ratio?N/A
P/B Ratio?3.77
EPS?-$1.04
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Employees
1.6K
Market Cap
1.4B
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed
2015-10-02
Address
NO. 4 THE FORUM
ST. HELIER,
Phone: 44 (0)15 3475 6700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
4
Momentum?
80
Short Sent.?
54
Piotroski F-Score?4/9Mixed
Altman Z-Score?0.28Distress
Confidence?53%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.26%High
Short Interest?12.9M
Days to Cover?6.0
Free Float105.4M
Avg Daily Volume2.1M
Settlement Date2026-10-30
Financial Health
Current Ratio?2.49Strong
Quick Ratio?2.34Strong
Cash Ratio?0.36Low
Debt/Equity?0.56Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
Peers
100
S&P
46
3.77FAIR▾
P/S?
Peers
100
S&P
71
1.82CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-13.2CHEAP▾
EV/Sales?
Peers
100
S&P
75
1.96CHEAP▾
Returns & Efficiency
ROE?
S&P
5
-34.7%WEAK▾
ROA?
S&P
3
-14.7%WEAK▾
Cash Flow & Enterprise
FCF?$-24607000
Enterprise Value?$1.4B
Fundamentals ratios updated end of day